Expression level of dihydropyrimidine dehydrogenase is associated with clinical outcome in patients with T1G3 bladder cancer treated with Bacillus Calmette-Guerin

Hiroki Ide, Eiji Kikuchi, Shuji Mikami, Akira Miyajima, Mototsugu Oya

Research output: Contribution to journalArticle

Abstract

Background: Recently, it has been shown that 5-fluorouracil (5-FU) with a strong dihydropyrimidine dehydrogenase (DPD) inhibitor elicits a significant response in bladder cancer with a high level of DPD. However, only a few studies investigated the association between the level of the enzyme that regulates the metabolism of 5-FU and prognosis in bladder cancer. Furthermore, to our knowledge, there has also been no such report in T1G3 bladder tumors treated with BCG. Therefore, we evaluated enzymes that regulate the metabolism of 5-FU in T1G3 tumors treated with BCG immunotherapy using the Danenberg tumor profile (DTP) method, a highly accurate measurement of RNA from paraffin-embedded specimens. Methods. This study included 28 patients with T1G3 bladder cancer, each of whom underwent complete transurethral tumor resection and BCG intravesical instillation at our institution. The median follow-up period was 39 months (range, 3 to 159 months). The DTP method was used to analyze the mRNA expression of 3 enzymes related to 5-FU: DPD, orotate phosphoribosyltransferase (OPRT), and thymidylate synthase (TS). Results: Among the 28 patients, 13 developed recurrences (46.4%) and 5 experienced disease progression (17.9%). An elevated DPD mRNA level was significantly associated with recurrence (p = 0.048) and progression (p = 0.045). However, TS and OPRT mRNA levels were not significantly associated with any other clinical features or outcomes. Furthermore, the high DPD group had a significantly lower recurrence-free survival rate than the low DPD group (p = 0.047). Among patients with low DPD, the 2- and 5-year recurrence-free survival rates were 88.9% and 74.1%, respectively; while among patients with high DPD, the corresponding rates were 61.3% and 36.8%, respectively. TS and OPRT were not significantly associated with recurrence-free survival rates. Conclusion: DPD is significantly associated with recurrence and progression among T1G3 bladder cancer patients treated with BCG.

Original languageEnglish
Article number646
JournalBMC Research Notes
Volume7
Issue number1
DOIs
Publication statusPublished - 2014 Sep 13

Fingerprint

Dihydrouracil Dehydrogenase (NADP)
Bacilli
Mycobacterium bovis
Urinary Bladder Neoplasms
Orotate Phosphoribosyltransferase
Tumors
Recurrence
Fluorouracil
Thymidylate Synthase
Survival Rate
Metabolism
Messenger RNA
Neoplasms
Enzymes
Intravesical Administration
Paraffin
Immunotherapy
Disease Progression
RNA

Keywords

  • 5-fluorouracil
  • Dihydropyrimidine dehydrogenase
  • S-1
  • Thymidylate synthase
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

@article{7285d425045f4e35ba2a62c6a506f095,
title = "Expression level of dihydropyrimidine dehydrogenase is associated with clinical outcome in patients with T1G3 bladder cancer treated with Bacillus Calmette-Guerin",
abstract = "Background: Recently, it has been shown that 5-fluorouracil (5-FU) with a strong dihydropyrimidine dehydrogenase (DPD) inhibitor elicits a significant response in bladder cancer with a high level of DPD. However, only a few studies investigated the association between the level of the enzyme that regulates the metabolism of 5-FU and prognosis in bladder cancer. Furthermore, to our knowledge, there has also been no such report in T1G3 bladder tumors treated with BCG. Therefore, we evaluated enzymes that regulate the metabolism of 5-FU in T1G3 tumors treated with BCG immunotherapy using the Danenberg tumor profile (DTP) method, a highly accurate measurement of RNA from paraffin-embedded specimens. Methods. This study included 28 patients with T1G3 bladder cancer, each of whom underwent complete transurethral tumor resection and BCG intravesical instillation at our institution. The median follow-up period was 39 months (range, 3 to 159 months). The DTP method was used to analyze the mRNA expression of 3 enzymes related to 5-FU: DPD, orotate phosphoribosyltransferase (OPRT), and thymidylate synthase (TS). Results: Among the 28 patients, 13 developed recurrences (46.4{\%}) and 5 experienced disease progression (17.9{\%}). An elevated DPD mRNA level was significantly associated with recurrence (p = 0.048) and progression (p = 0.045). However, TS and OPRT mRNA levels were not significantly associated with any other clinical features or outcomes. Furthermore, the high DPD group had a significantly lower recurrence-free survival rate than the low DPD group (p = 0.047). Among patients with low DPD, the 2- and 5-year recurrence-free survival rates were 88.9{\%} and 74.1{\%}, respectively; while among patients with high DPD, the corresponding rates were 61.3{\%} and 36.8{\%}, respectively. TS and OPRT were not significantly associated with recurrence-free survival rates. Conclusion: DPD is significantly associated with recurrence and progression among T1G3 bladder cancer patients treated with BCG.",
keywords = "5-fluorouracil, Dihydropyrimidine dehydrogenase, S-1, Thymidylate synthase, Urothelial carcinoma",
author = "Hiroki Ide and Eiji Kikuchi and Shuji Mikami and Akira Miyajima and Mototsugu Oya",
year = "2014",
month = "9",
day = "13",
doi = "10.1186/1756-0500-7-646",
language = "English",
volume = "7",
journal = "BMC Research Notes",
issn = "1756-0500",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Expression level of dihydropyrimidine dehydrogenase is associated with clinical outcome in patients with T1G3 bladder cancer treated with Bacillus Calmette-Guerin

AU - Ide, Hiroki

AU - Kikuchi, Eiji

AU - Mikami, Shuji

AU - Miyajima, Akira

AU - Oya, Mototsugu

PY - 2014/9/13

Y1 - 2014/9/13

N2 - Background: Recently, it has been shown that 5-fluorouracil (5-FU) with a strong dihydropyrimidine dehydrogenase (DPD) inhibitor elicits a significant response in bladder cancer with a high level of DPD. However, only a few studies investigated the association between the level of the enzyme that regulates the metabolism of 5-FU and prognosis in bladder cancer. Furthermore, to our knowledge, there has also been no such report in T1G3 bladder tumors treated with BCG. Therefore, we evaluated enzymes that regulate the metabolism of 5-FU in T1G3 tumors treated with BCG immunotherapy using the Danenberg tumor profile (DTP) method, a highly accurate measurement of RNA from paraffin-embedded specimens. Methods. This study included 28 patients with T1G3 bladder cancer, each of whom underwent complete transurethral tumor resection and BCG intravesical instillation at our institution. The median follow-up period was 39 months (range, 3 to 159 months). The DTP method was used to analyze the mRNA expression of 3 enzymes related to 5-FU: DPD, orotate phosphoribosyltransferase (OPRT), and thymidylate synthase (TS). Results: Among the 28 patients, 13 developed recurrences (46.4%) and 5 experienced disease progression (17.9%). An elevated DPD mRNA level was significantly associated with recurrence (p = 0.048) and progression (p = 0.045). However, TS and OPRT mRNA levels were not significantly associated with any other clinical features or outcomes. Furthermore, the high DPD group had a significantly lower recurrence-free survival rate than the low DPD group (p = 0.047). Among patients with low DPD, the 2- and 5-year recurrence-free survival rates were 88.9% and 74.1%, respectively; while among patients with high DPD, the corresponding rates were 61.3% and 36.8%, respectively. TS and OPRT were not significantly associated with recurrence-free survival rates. Conclusion: DPD is significantly associated with recurrence and progression among T1G3 bladder cancer patients treated with BCG.

AB - Background: Recently, it has been shown that 5-fluorouracil (5-FU) with a strong dihydropyrimidine dehydrogenase (DPD) inhibitor elicits a significant response in bladder cancer with a high level of DPD. However, only a few studies investigated the association between the level of the enzyme that regulates the metabolism of 5-FU and prognosis in bladder cancer. Furthermore, to our knowledge, there has also been no such report in T1G3 bladder tumors treated with BCG. Therefore, we evaluated enzymes that regulate the metabolism of 5-FU in T1G3 tumors treated with BCG immunotherapy using the Danenberg tumor profile (DTP) method, a highly accurate measurement of RNA from paraffin-embedded specimens. Methods. This study included 28 patients with T1G3 bladder cancer, each of whom underwent complete transurethral tumor resection and BCG intravesical instillation at our institution. The median follow-up period was 39 months (range, 3 to 159 months). The DTP method was used to analyze the mRNA expression of 3 enzymes related to 5-FU: DPD, orotate phosphoribosyltransferase (OPRT), and thymidylate synthase (TS). Results: Among the 28 patients, 13 developed recurrences (46.4%) and 5 experienced disease progression (17.9%). An elevated DPD mRNA level was significantly associated with recurrence (p = 0.048) and progression (p = 0.045). However, TS and OPRT mRNA levels were not significantly associated with any other clinical features or outcomes. Furthermore, the high DPD group had a significantly lower recurrence-free survival rate than the low DPD group (p = 0.047). Among patients with low DPD, the 2- and 5-year recurrence-free survival rates were 88.9% and 74.1%, respectively; while among patients with high DPD, the corresponding rates were 61.3% and 36.8%, respectively. TS and OPRT were not significantly associated with recurrence-free survival rates. Conclusion: DPD is significantly associated with recurrence and progression among T1G3 bladder cancer patients treated with BCG.

KW - 5-fluorouracil

KW - Dihydropyrimidine dehydrogenase

KW - S-1

KW - Thymidylate synthase

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84907435787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907435787&partnerID=8YFLogxK

U2 - 10.1186/1756-0500-7-646

DO - 10.1186/1756-0500-7-646

M3 - Article

C2 - 25218240

AN - SCOPUS:84907435787

VL - 7

JO - BMC Research Notes

JF - BMC Research Notes

SN - 1756-0500

IS - 1

M1 - 646

ER -